Related references
Note: Only part of the references are listed.A Dual PI3K/mTOR Inhibitor, PI-103, Cooperates with Stem Cell-Delivered TRAIL in Experimental Glioma Models
Tugba Bagci-Onder et al.
CANCER RESEARCH (2011)
Retinoic Acid Enhances TRAIL-Induced Apoptosis in Cancer Cells by Upregulating TRAIL Receptor 1 Expression
Latha Dhandapani et al.
CANCER RESEARCH (2011)
Acquired Resistance of Non-Small Cell Lung Cancer Cells to MET Kinase Inhibition Is Mediated by a Switch to Epidermal Growth Factor Receptor Dependency
Ultan McDermott et al.
CANCER RESEARCH (2010)
Death Receptor Agonists as a Targeted Therapy for Cancer
Jeffrey Wiezorek et al.
CLINICAL CANCER RESEARCH (2010)
Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation
Annie Yang et al.
CURRENT OPINION IN CELL BIOLOGY (2010)
被撤回的出版物: Celastrol, a Triterpene, Enhances TRAIL-induced Apoptosis through the Down-regulation of Cell Survival Proteins and Up-regulation of Death Receptors (Retracted article. See vol. 291, pg. 16920, 2016)
Bokyung Sung et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Selective Inhibition of Histone Deacetylases Sensitizes Malignant Cells to Death Receptor Ligands
Tabitha E. Wood et al.
MOLECULAR CANCER THERAPEUTICS (2010)
β-Ionone Enhances TRAIL-Induced Apoptosis in Hepatocellular Carcinoma Cells through Sp1-Dependent Upregulation of DR5 and Downregulation of NF-κB Activity
Mun-Ock Kim et al.
MOLECULAR CANCER THERAPEUTICS (2010)
被撤回的出版物: Garcinol Potentiates TRAIL-Induced Apoptosis through Modulation of Death Receptors and Antiapoptotic Proteins (Retracted article. See vol. 17, pg. 2073, 2018)
Sahdeo Prasad et al.
MOLECULAR CANCER THERAPEUTICS (2010)
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy
Jeffrey J. Raizer et al.
NEURO-ONCOLOGY (2010)
Predominant antitumor effects by fully human anti-TRAIL-receptor2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo
Motoo Nagane et al.
NEURO-ONCOLOGY (2010)
Novel HTS Strategy Identifies TRAIL-Sensitizing Compounds Acting Specifically Through the Caspase-8 Apoptotic Axis
Darren Finlay et al.
PLOS ONE (2010)
A Novel Molecule Integrating Therapeutic and Diagnostic Activities Reveals Multiple Aspects of Stem Cell-Based Therapy
Shawn D. Hingtgen et al.
STEM CELLS (2010)
Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma
Jason T. Huse et al.
NATURE REVIEWS CANCER (2010)
Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma
B. Neyns et al.
ANNALS OF ONCOLOGY (2009)
PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells
Hal E. Crosswell et al.
BMC CANCER (2009)
A cell-based high-throughput screen to identify synergistic TRAIL sensitizers
Nancy Lynn Booth et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Clinical Studies of Histone Deacetylase Inhibitors
H. Miles Prince et al.
CLINICAL CANCER RESEARCH (2009)
Reactivation of death receptor 4 (DR4) expression sensitizes medulloblastoma cell lines to TRAIL
Dolly G. Aguilera et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis
Sabrina L. Spencer et al.
NATURE (2009)
Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy
Laura S. Sasportas et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
ABT-737 Induces Expression of the Death Receptor 5 and Sensitizes Human Cancer Cells to TRAIL-induced Apoptosis
Jin H. Song et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
To kill a tumor cell: the potential of proapoptotic receptor agonists
Avi Ashkenazi et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Bimodal viral vectors and in vivo imaging reveal the fate of human neural stem cells in experimental glioma model
Khalid Shah et al.
JOURNAL OF NEUROSCIENCE (2008)
Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide
Shawn Hingtgen et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Quantitative analysis of pathways controlling extrinsic apoptosis in single cells
John G. Albeck et al.
MOLECULAR CELL (2008)
Directing cancer cells to self-destruct with pro-apoptotic receptor agonists
Avi Ashkenazi
NATURE REVIEWS DRUG DISCOVERY (2008)
Mechanisms of disease: temozolomide and glioblastoma - look to the future
Maciej M. Mrugala et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2008)
Modeling a Snap-Action, Variable-Delay Switch Controlling Extrinsic Cell Death
John G. Albeck et al.
PLOS BIOLOGY (2008)
The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells
Xiangguo Liu et al.
CANCER RESEARCH (2007)
Tumor therapy mediated by lentiviral expression of shBcl-2 and S-TRAIL
Norman Kock et al.
NEOPLASIA (2007)
Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1
Stavroula Baritaki et al.
MOLECULAR CANCER THERAPEUTICS (2007)
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma
Qi-Wen Fan et al.
CANCER CELL (2006)
Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein
T Yoshida et al.
CANCER RESEARCH (2005)
HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma
TR Singh et al.
ONCOGENE (2005)
Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression
K Shah et al.
ANNALS OF NEUROLOGY (2005)
Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells
S Nakata et al.
ONCOGENE (2004)
Share Paper
